354 related articles for article (PubMed ID: 36275669)
21. Enhancing Immunotherapy in Ovarian Cancer: The Emerging Role of Metformin and Statins.
Almeida-Nunes DL; Silvestre R; Dinis-Oliveira RJ; Ricardo S
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203494
[TBL] [Abstract][Full Text] [Related]
22. Potential role of immune cell therapy in gynecological cancer and future promises: a comprehensive review.
Dasgupta S; Gayen S; Chakraborty T; Afrose N; Pal R; Mahata S; Nasare V; Roy S
Med Oncol; 2024 Mar; 41(5):98. PubMed ID: 38536512
[TBL] [Abstract][Full Text] [Related]
23. Clinical Applications of Combined Immunotherapy Approaches in Gastrointestinal Cancer: A Case-Based Review.
Eralp Y; Ates U
Vaccines (Basel); 2023 Sep; 11(10):. PubMed ID: 37896948
[TBL] [Abstract][Full Text] [Related]
24. Unlocking ovarian cancer heterogeneity: advancing immunotherapy through single-cell transcriptomics.
Balan D; Kampan NC; Plebanski M; Abd Aziz NH
Front Oncol; 2024; 14():1388663. PubMed ID: 38873253
[TBL] [Abstract][Full Text] [Related]
25. Exploring the tumor immune microenvironment in ovarian cancer: a way-out to the therapeutic roadmap.
Bhat BA; Saifi I; Khamjan NA; Hamdani SS; Algaissi A; Rashid S; Alshehri MM; Ganie SA; Lohani M; Abdelwahab SI; Dar SA
Expert Opin Ther Targets; 2023; 27(9):841-860. PubMed ID: 37712621
[TBL] [Abstract][Full Text] [Related]
26. Nucleic acid-based vaccine for ovarian cancer cells; bench to bedside.
Al-Hawary SIS; Jasim SA; Hjazi A; Oghenemaro EF; Kaur I; Kumar A; Al-Ani AM; Alwaily ER; Redhee AH; Mustafa YF
Cell Biochem Funct; 2024 Mar; 42(2):e3978. PubMed ID: 38515237
[TBL] [Abstract][Full Text] [Related]
27. RAS signaling and immune cells: a sinister crosstalk in the tumor microenvironment.
Liu Y; Xie B; Chen Q
J Transl Med; 2023 Sep; 21(1):595. PubMed ID: 37670322
[TBL] [Abstract][Full Text] [Related]
28. Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment.
Johnson RL; Cummings M; Thangavelu A; Theophilou G; de Jong D; Orsi NM
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944851
[TBL] [Abstract][Full Text] [Related]
29. Unlocking the 'ova'-coming power: immunotherapy's role in shaping the future of ovarian cancer treatment.
Haines NA; Fowler MG; Zeh BG; Kriete CB; Bai Q; Wakefield MR; Fang Y
Med Oncol; 2024 Jan; 41(3):67. PubMed ID: 38286890
[TBL] [Abstract][Full Text] [Related]
30. Editorial: Community series in novel insights into immunotherapy targeting tumor microenvironment in ovarian cancer: volume II.
Tong A; Wang HT; Wei XW; Liang X
Front Immunol; 2023; 14():1338119. PubMed ID: 38094303
[No Abstract] [Full Text] [Related]
31. Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches.
Palaia I; Tomao F; Sassu CM; Musacchio L; Benedetti Panici P
Onco Targets Ther; 2020; 13():6109-6129. PubMed ID: 32617007
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapies in sarcoma: Updates and future perspectives.
Ghosn M; El Rassy E; Kourie HR
World J Clin Oncol; 2017 Apr; 8(2):145-150. PubMed ID: 28439495
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy in pancreatic cancer treatment: a new frontier.
Thind K; Padrnos LJ; Ramanathan RK; Borad MJ
Therap Adv Gastroenterol; 2017 Jan; 10(1):168-194. PubMed ID: 28286568
[TBL] [Abstract][Full Text] [Related]
34. Spontaneous Regression of Ovarian Carcinoma After Septic Peritonitis; A Unique Case Report.
Roelofsen T; Wefers C; Gorris MAJ; Textor JC; Massuger LFAG; de Vries IJM; van Altena AM
Front Oncol; 2018; 8():562. PubMed ID: 30555799
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoints, their control by immunotherapy and ovarian cancer.
Bose CK
Contemp Oncol (Pozn); 2017; 21(3):189-196. PubMed ID: 29180924
[TBL] [Abstract][Full Text] [Related]
36. Review of cancer therapies for the perioperative physician.
Dabo-Trubelja A; Gottumukkala V
Perioper Med (Lond); 2023 Jun; 12(1):25. PubMed ID: 37312150
[TBL] [Abstract][Full Text] [Related]
37. [Ⅲ. Cancer Immunotherapies for Ovarian Cancer; Where We Stand, Perspectives and Issues].
Hamanishi J; Mandai M
Gan To Kagaku Ryoho; 2024 Feb; 51(2):142-148. PubMed ID: 38449399
[No Abstract] [Full Text] [Related]
38. Immunotherapeutic Approaches in Ovarian Cancer.
Yoon H; Kim A; Jang H
Curr Issues Mol Biol; 2023 Feb; 45(2):1233-1249. PubMed ID: 36826026
[TBL] [Abstract][Full Text] [Related]
39. Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints.
Franzese O; Graziani G
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428727
[TBL] [Abstract][Full Text] [Related]
40. Immune pathway through endometriosis to ovarian cancer.
Calmon MS; Lemos FFB; Silva Luz M; Rocha Pinheiro SL; de Oliveira Silva LG; Correa Santos GL; Rocha GR; Freire de Melo F
World J Clin Oncol; 2024 Apr; 15(4):496-522. PubMed ID: 38689629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
